The Gujarat High Court has sanctioned the scheme of amalgamation of Zyg Pharma with the company with effect from October 1, 2015. As for the India business, domestic formulations recorded revenues of Rs 447 crore for the quarter, up 13 per cent. The Brazil business, however, declined by 16 per cent to Rs 119 crore.
The US revenues which stood at Rs 514 crore, were up 128 per cent.
For the full year, the revenues were up 43 per cent to Rs 6,676 crore, while the PAT was up 129 per cent to Rs 2,930 crore.